Emergent BioSolutions Inc. (0IGA.L)
USD 4.41
(-11.45%)
USD 4.41
(-11.45%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.83 Billion USD | -42.05% |
| 2022 | 3.16 Billion USD | 7.02% |
| 2021 | 2.95 Billion USD | 2.63% |
| 2020 | 2.88 Billion USD | 23.78% |
| 2019 | 2.32 Billion USD | 4.48% |
| 2018 | 2.22 Billion USD | 108.32% |
| 2017 | 1.07 Billion USD | 10.32% |
| 2016 | 970.11 Million USD | -7.04% |
| 2015 | 1.04 Billion USD | 10.4% |
| 2014 | 945.26 Million USD | 50.85% |
| 2013 | 626.63 Million USD | 11.06% |
| 2012 | 564.23 Million USD | 3.18% |
| 2011 | 546.86 Million USD | 9.3% |
| 2010 | 500.31 Million USD | 45.15% |
| 2009 | 344.68 Million USD | 18.54% |
| 2008 | 290.78 Million USD | 6.32% |
| 2007 | 273.5 Million USD | 14.8% |
| 2006 | 238.25 Million USD | 137.47% |
| 2005 | 100.33 Million USD | 45.29% |
| 2004 | 69.05 Million USD | 0.0% |
| 2002 | 22.79 Million USD | -10.36% |
| 2001 | 25.42 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.51 Billion USD | -16.08% |
| 2024 Q1 | 1.8 Billion USD | -1.71% |
| 2023 Q2 | 2.17 Billion USD | -26.14% |
| 2023 Q4 | 1.83 Billion USD | -3.07% |
| 2023 FY | 1.83 Billion USD | -42.05% |
| 2023 Q1 | 2.94 Billion USD | -6.85% |
| 2023 Q3 | 1.89 Billion USD | -13.11% |
| 2022 FY | 3.16 Billion USD | 7.02% |
| 2022 Q4 | 3.16 Billion USD | 8.87% |
| 2022 Q2 | 2.73 Billion USD | -1.62% |
| 2022 Q3 | 2.9 Billion USD | 6.33% |
| 2022 Q1 | 2.78 Billion USD | -6.04% |
| 2021 FY | 2.95 Billion USD | 2.63% |
| 2021 Q1 | 2.9 Billion USD | 0.59% |
| 2021 Q2 | 2.91 Billion USD | 0.52% |
| 2021 Q3 | 2.86 Billion USD | -1.64% |
| 2021 Q4 | 2.95 Billion USD | 3.19% |
| 2020 Q1 | 2.27 Billion USD | -2.17% |
| 2020 FY | 2.88 Billion USD | 23.78% |
| 2020 Q4 | 2.88 Billion USD | 10.2% |
| 2020 Q3 | 2.61 Billion USD | 6.09% |
| 2020 Q2 | 2.46 Billion USD | 8.22% |
| 2019 Q3 | 2.33 Billion USD | 0.54% |
| 2019 Q4 | 2.32 Billion USD | -0.19% |
| 2019 Q2 | 2.32 Billion USD | 7.78% |
| 2019 FY | 2.32 Billion USD | 4.48% |
| 2019 Q1 | 2.15 Billion USD | -3.4% |
| 2018 Q2 | 1.13 Billion USD | 6.59% |
| 2018 Q1 | 1.06 Billion USD | -0.16% |
| 2018 FY | 2.22 Billion USD | 108.32% |
| 2018 Q3 | 1.17 Billion USD | 3.05% |
| 2018 Q4 | 2.22 Billion USD | 89.96% |
| 2017 FY | 1.07 Billion USD | 10.32% |
| 2017 Q4 | 1.07 Billion USD | 4.49% |
| 2017 Q3 | 1.02 Billion USD | 5.54% |
| 2017 Q2 | 970.48 Million USD | 1.98% |
| 2017 Q1 | 951.63 Million USD | -1.9% |
| 2016 Q4 | 970.11 Million USD | 4.09% |
| 2016 FY | 970.11 Million USD | -7.04% |
| 2016 Q1 | 1.03 Billion USD | -0.74% |
| 2016 Q2 | 1.05 Billion USD | 1.99% |
| 2016 Q3 | 932.02 Million USD | -11.78% |
| 2015 Q3 | 976.54 Million USD | 3.52% |
| 2015 Q1 | 917.84 Million USD | -2.9% |
| 2015 Q4 | 1.04 Billion USD | 6.87% |
| 2015 FY | 1.04 Billion USD | 10.4% |
| 2015 Q2 | 943.32 Million USD | 2.78% |
| 2014 Q2 | 837.24 Million USD | 1.7% |
| 2014 Q1 | 823.25 Million USD | 31.38% |
| 2014 FY | 945.26 Million USD | 50.85% |
| 2014 Q4 | 945.26 Million USD | 8.74% |
| 2014 Q3 | 869.29 Million USD | 3.83% |
| 2013 Q4 | 626.63 Million USD | 5.23% |
| 2013 Q1 | 538.38 Million USD | -4.58% |
| 2013 Q2 | 555.61 Million USD | 3.2% |
| 2013 FY | 626.63 Million USD | 11.06% |
| 2013 Q3 | 595.46 Million USD | 7.17% |
| 2012 FY | 564.23 Million USD | 3.18% |
| 2012 Q3 | 540.02 Million USD | 2.44% |
| 2012 Q2 | 527.14 Million USD | 2.42% |
| 2012 Q1 | 514.68 Million USD | -5.88% |
| 2012 Q4 | 564.23 Million USD | 4.48% |
| 2011 FY | 546.86 Million USD | 9.3% |
| 2011 Q4 | 546.86 Million USD | 6.61% |
| 2011 Q3 | 512.96 Million USD | 3.84% |
| 2011 Q2 | 493.98 Million USD | 4.82% |
| 2011 Q1 | 471.27 Million USD | -5.8% |
| 2010 Q4 | 500.31 Million USD | 36.61% |
| 2010 Q1 | 342.79 Million USD | -0.55% |
| 2010 Q2 | 345.74 Million USD | 0.86% |
| 2010 Q3 | 366.23 Million USD | 5.93% |
| 2010 FY | 500.31 Million USD | 45.15% |
| 2009 FY | 344.68 Million USD | 18.54% |
| 2009 Q4 | 344.68 Million USD | 8.8% |
| 2009 Q3 | 316.8 Million USD | -2.94% |
| 2009 Q2 | 326.38 Million USD | 7.44% |
| 2009 Q1 | 303.78 Million USD | 4.47% |
| 2008 Q2 | 277.91 Million USD | 1.56% |
| 2008 Q4 | 290.78 Million USD | 1.18% |
| 2008 Q1 | 273.64 Million USD | 0.05% |
| 2008 FY | 290.78 Million USD | 6.32% |
| 2008 Q3 | 287.39 Million USD | 3.41% |
| 2007 Q3 | 226.75 Million USD | 9.54% |
| 2007 Q2 | 206.99 Million USD | 1.52% |
| 2007 Q4 | 273.5 Million USD | 20.62% |
| 2007 Q1 | 203.89 Million USD | -14.42% |
| 2007 FY | 273.5 Million USD | 14.8% |
| 2006 Q4 | 238.25 Million USD | 82.11% |
| 2006 FY | 238.25 Million USD | 137.47% |
| 2006 Q3 | 130.83 Million USD | 0.0% |
| 2005 Q4 | 100.33 Million USD | 0.0% |
| 2005 FY | 100.33 Million USD | 45.29% |
| 2004 FY | 69.05 Million USD | 0.0% |
| 2004 Q4 | 69.05 Million USD | 0.0% |
| 2002 FY | 22.79 Million USD | -10.36% |
| 2001 Q4 | 2.95 Billion USD | 0.0% |
| 2001 FY | 25.42 Million USD | 0.0% |
| 2000 Q4 | 3.16 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -120.623% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -95.802% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -135.885% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1008.674% |
| bluebird bio, Inc. | 619.16 Million USD | -196.353% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -1358.075% |
| Imunon, Inc. | 21.91 Million USD | -8271.632% |
| Editas Medicine, Inc. | 499.15 Million USD | -267.603% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 93.123% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 45.318% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -53.074% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 43.566% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -30.229% |
| Verastem, Inc. | 149.71 Million USD | -1125.571% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 97.736% |
| Waters Corporation | 4.62 Billion USD | 60.342% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.141% |
| Biogen Inc. | 26.84 Billion USD | 93.165% |
| Nektar Therapeutics | 398.03 Million USD | -360.992% |
| Perrigo Company plc | 10.8 Billion USD | 83.024% |
| Dynavax Technologies Corporation | 997.09 Million USD | -84.024% |
| Illumina, Inc. | 10.11 Billion USD | 81.852% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -6390.077% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -135.138% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -724.652% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -2693.271% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 73.18% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1009.908% |
| Evolus, Inc. | 188.99 Million USD | -870.857% |
| Adicet Bio, Inc. | 207.29 Million USD | -785.164% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -829.51% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 94.453% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -791.611% |
| FibroGen, Inc. | 423.52 Million USD | -333.241% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 82.952% |
| OPKO Health, Inc. | 2.01 Billion USD | 8.788% |
| Homology Medicines, Inc. | 47.05 Million USD | -3799.314% |
| Geron Corporation | 394.07 Million USD | -365.621% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 52.09% |
| Exelixis, Inc. | 2.94 Billion USD | 37.638% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -397.951% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1088.515% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -41.04% |
| Zoetis Inc. | 14.28 Billion USD | 87.156% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -211.933% |
| Abeona Therapeutics Inc. | 64 Million USD | -2766.942% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 91.927% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -3179.594% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 38.634% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 43.794% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -195.229% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -5.863% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -74.877% |
| Insmed Incorporated | 1.32 Billion USD | -37.979% |
| TG Therapeutics, Inc. | 329.58 Million USD | -456.727% |
| Incyte Corporation | 6.78 Billion USD | 72.945% |